Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

Blood

Volumn 99, Issue 12, 2002, Pages 4343-4349

  Estey, Elihu H ^a,b   Thall, Peter F ^a   Giles, Francis J ^a   Wang, Xue Mei ^a   Cortes, Jorge E ^a   Beran, Miloslav ^a   Pierce, Sherry A ^a   Thomas, Deborah A ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 11; LISOFYLLINE; RETINOIC ACID; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG INFUSION; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; SURVIVAL RATE;

EID: 0037097707     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.12.4343     Document Type: Article

References (21)

1. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
2. How I treat older patients with AML
3. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
4. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials
5. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials
6. Nonparametric estimator from incomplete observations
7. Evaluation of survival data and two new rank order statistics arising in its consideration
8. Regression models and life tables
9. Robust locally weighted regression and smoothing scatterplots
10. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
11. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine
12. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysptastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
13. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuousinfusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF
14. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
15. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
16. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin